Why We Think Nova Leap Health Corp.'s (CVE:NLH) CEO Compensation Is Not Excessive At All

Key Insights

• Nova Leap Health's Annual General Meeting to take place on 23rd of May
• CEO Chris Dobbin's total compensation includes salary of US$55.6k
• The total compensation is 60% less than the average for the industry
• Nova Leap Health's three-year loss to shareholders was 47% while its EPS grew by 14% over the past three years

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Shareholders may be wondering what CEO Chris Dobbin plans to do to improve the less than great performance at Nova Leap Health Corp. (CVE:NLH) recently. They will get a chance to exercise their voting power to influence the future direction of the company in the next AGM on 23rd of May. It has been shown that setting appropriate executive remuneration incentivises the management to act in the interests of shareholders. We think CEO compensation looks appropriate given the data we have put together.

View our latest analysis for Nova Leap Health

How Does Total Compensation For Chris Dobbin Compare With Other Companies In The Industry?

At the time of writing, our data shows that Nova Leap Health Corp. has a market capitalization of CA$21m, and reported total annual CEO compensation of US$268k for the year to December 2024. That's mostly flat as compared to the prior year's compensation. While this analysis focuses on total compensation, it's worth acknowledging that the salary portion is lower, valued at US$56k.

For comparison, other companies in the Canadian Healthcare industry with market capitalizations below CA$279m, reported a median total CEO compensation of US$668k. This suggests that Chris Dobbin is paid below the industry median. What's more, Chris Dobbin holds CA$2.3m worth of shares in the company in their own name, indicating that they have a lot of skin in the game.

On an industry level, around 30% of total compensation represents salary and 70% is other remuneration. Nova Leap Health sets aside a smaller share of compensation for salary, in comparison to the overall industry. If total compensation is slanted towards non-salary benefits, it indicates that CEO pay is linked to company performance.

Nova Leap Health Corp.'s Growth

Nova Leap Health Corp. has seen its earnings per share (EPS) increase by 14% a year over the past three years. In the last year, its revenue changed by just 0.8%.

Overall this is a positive result for shareholders, showing that the company has improved in recent years. It's nice to see revenue heading northwards, as this is consistent with healthy business conditions. While we don't have analyst forecasts for the company, shareholders might want to examine this detailed historical graph of earnings, revenue and cash flow.

Has Nova Leap Health Corp. Been A Good Investment?

Few Nova Leap Health Corp. shareholders would feel satisfied with the return of -47% over three years. Therefore, it might be upsetting for shareholders if the CEO were paid generously.

To Conclude...

The fact that shareholders are sitting on a loss is certainly disheartening. The share price trend has diverged with the robust growth in EPS however, suggesting there may be other factors that could be driving the price performance. A key focus for the board and management will be how to align the share price with fundamentals. In the upcoming AGM, shareholders should take this opportunity to raise these concerns with the board and revisit their investment thesis with regards to the company.

CEO compensation is a crucial aspect to keep your eyes on but investors also need to keep their eyes open for other issues related to business performance. That's why we did some digging and identified 3 warning signs for Nova Leap Health that investors should think about before committing capital to this stock.

Arguably, business quality is much more important than CEO compensation levels. So check out this free list of interesting companies that have HIGH return on equity and low debt.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.